中文名稱    磷酸化紅細胞生成素受體抗體    

英文名稱    phospho-EPO Receptor (Tyr368)  

別    名    EPO Receptor (phospho Y368); p-EPO Receptor (phospho Y368); EPOR (phospho Y368); p-EPOR (phospho Y368); erythropoietin receptor; EPO R; EPO Receptor; Erythropoietin receptor precursor; EPOR_HUMAN; MGC138358.    

供 應 商    遠慕生物        

產品類型    磷酸化抗體     

研究領域    腫瘤  免疫學      

抗體來源    Rabbit    

克隆類型    Polyclonal    

交叉反應    Human, Mouse, Rat,     

產品應用    WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 磷酸化紅細胞生成素受體抗體（石蠟切片需做抗原修復） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.    

分 子 量    56kDa    

細胞定位    細胞膜 細胞外基質 分泌型蛋白     

性    狀    Lyophilized or Liquid    

濃    度    1mg/1ml    

免 疫 原    KLH conjugated synthesised phosphopeptide derived from human EPO Receptor around the phosphorylation site of Tyr368    

亞    型    IgG    

純化方法    affinity purified by Protein A    

儲 存 液    Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4    

保存條件    Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.    

磷酸化紅細胞生成素受體抗體產品介紹    background:

The erythropoietin receptor (EPOR) is a member of the cytokine receptor family. There are several isoforms including: EPOR-F (full length), EPOR-S (soluble form), and EPOR-T (truncated form). Upon erythropoietin (EPO) binding, the EPOR activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated EPOR appears to have a role in erythroid cell survival. Defects in the EPOR may produce erythroleukemia and familial erythrocytosis. A functional EPOR is found in the cardiovascular system, including endothelial cells and cardiomyocytes, and data suggest that the EPO/EPO receptor system plays an important role in cardiac function. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis.

Function:
Forms homodimers on EPO stimulation. The tyrosine-phosphorylated form interacts with several SH2 domain-containing proteins including LYN, the adapter protein APS, PTPN6, PTPN11, JAK2, PI3 kinases, STAT5A/B, SOCS3, CRKL. Interacts with INPP5D/SHIP1. The N-terminal SH2 domain of PTPN6 binds Tyr-454 and inhibits signaling through dephosphorylation of JAK2. APS binding also inhibits the JAK-STAT signaling. Binding to PTPN11, preferentially through the N-terminal SH2 domain, promotes mitogenesis and phosphorylation of PTPN11. Binding of JAK2 (through its N-terminal) promotes cell-surface expression. Interaction with the ubiquitin ligase NOSIP mediates EPO-induced cell proliferation. Interacts with ATXN2L.

Subcellular Location:
Cell membrane; Single-pass type I membrane protein. 
Isoform EPOR-S: Secreted. Note=Secreted and located to the cell surface.

Tissue Specificity:
Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors. Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EPOR-T is the most abundant from in early-stage erythroid progenitor cells.

Similarity:
Belongs to the type I cytokine receptor family. 
Type 1 subfamily. Contains 1 fibronectin type-III domain.